ESMO 2023 | Using multimodal artificial intelligence models in the STAMPEDE trials

Charles Parker, MBBS, UCL Cancer Institute, London, UK, comments on the use of multimodal artificial intelligence (MMAI)-derived models in the STAMPEDE trials (NCT00268476), which assessed androgen deprivation therapy in patients with high-risk localized/metastatic prostate cancer. Using biopsy samples, certain clinical variables were associated with a positive prognosis, enabling future stratification of patients. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.